But the pursuit is no longer fringe. Animal longevity, human function, organ preservation, and connectomics are moving at very different speeds. This survey separates the strongest signals from the longest bets.
The order combines replication, mechanism, human data, and tractability. “Promising” means scientifically promising, not proven, safe, or commercially ready.
The most informative trials are not a clean victory column. They show where biomarkers diverge from outcomes, where subgroups matter, and where a missed primary endpoint outweighs a promising secondary result.
Laromestrocel produced a +63.4 m change in 6-minute walk at month 9 in ambulatory frailty (p=0.0077). TIE-2 emerged as a candidate response biomarker. Phase 3 and durability remain open.
Longeveron result ↗Intermittent dasatinib + quercetin for 20 weeks did not improve the primary bone-resorption endpoint (P=0.611). A high-senescence subgroup showed increased radial bone density. No serious adverse events were reported.
NIA trial summary ↗The PEARL trial tested 5 or 10 mg weekly. The primary aging endpoint did not move significantly. Secondary signals suggested preserved lean mass in women and bone mineral in men; the trial was likely safe over one year.
PEARL summary ↗NMN raises circulating NAD+, yet a 2024 meta-analysis found no significant difference from control in fasting glucose, triglycerides, or total, LDL, and HDL cholesterol. This is the field's cleanest warning against treating biomarker movement as health benefit.
Clinical review ↗Partial reprogramming now has its first human data. On 8 October 2026 Life Biosciences reported that ER-100, an AAV therapy expressing the OSK reprogramming factors under a doxycycline switch, was well tolerated through Day 56 in the first three participants of its Phase 1 trial in open-angle glaucoma (NCT07290244), with no dose-limiting toxicities or serious adverse events, and the safety board cleared escalation to a higher dose. Two of three participants showed early visual-field improvement signals. This is company-reported, open-label safety data in three people with no control group: it establishes that in vivo OSK expression has begun human testing, not that reprogramming works in humans.
Life Biosciences release ↗The largest rigorous test of an NAD+ precursor so far came back negative. In the Phase 3 NOPARK trial (JAMA, 2026; 410 people with early Parkinson disease, one year of nicotinamide riboside), the supplement raised NAD metabolism as intended but produced no clinical benefit, with disease scores slightly worse than placebo. This does not settle NAD+ boosting for other conditions, but it removes Parkinson disease as a supporting example and shows that raising NAD levels is not, by itself, evidence of a clinical effect.
NOPARK report ↗Cryonics, structural brain preservation, and emulation are often collapsed into one idea. Their evidence, failure modes, and definitions of continuity are not the same.
Legal-death preservation uses cryoprotectant perfusion and storage near −196 °C. Alcor lists roughly $80k for neuropreservation and $200k for whole body; Cryonics Institute lists $28k plus roughly $60k standby and transport.
Evidence boundaryNo full mammal has ever been cooled to cryogenic temperatures and revived. Organ nanowarming is the strongest adjacent result, not proof of human revival.
Provider landscape ↗Aldehyde-stabilized cryopreservation preserves microscopic structure by fixation and vitrification. Rabbit and pig brains passed independent prize evaluation, but the process crosslinks proteins and preserves structure rather than viable tissue.
Evidence boundaryA complete human connectome is estimated near 1 zettabyte. Serious assessments place human whole-brain emulation several decades to more than a century away.
Large Mammal Prize context ↗Rat kidneys were vitrified at −122 °C, stored for up to 100 days, rewarmed in roughly 90 seconds, and transplanted into five rats. Full life-sustaining function returned within roughly 30 days. Cryoprotectant toxicity was the limiting factor.
Primary paper ↗The adult fruit-fly connectome contains about 130,000 neurons and took roughly 12 years. A mouse has about 70 million neurons and is not technically feasible today, according to the Allen Institute.
Connectome report ↗The preservation field's next scale test has been passed at preprint stage. Reported on 15 October 2026, porcine kidneys of about 100 g were vitrified with a new cryoprotectant, stored at −150 °C for up to a year, nanowarmed, and recovered function on machine perfusion approaching standard cold storage; acutely transplanted organs reperfused at once and produced urine. The work is a bioRxiv preprint that has not yet passed peer review, and the transplants were acute experiments, not long-term graft survival.
Preprint ↗Large private labs, public research programs, and philanthropy now sustain a serious geroscience ecosystem. Funding totals vary sharply with the definition of “longevity.”
Cellular reprogramming and senescence; acquired Dorian Therapeutics in May 2025.
Committed over roughly two years, making it the largest philanthropic funder of geroscience globally.
Ten Milestone 2 teams received $1M each in August 2026 and now target muscle, cognitive, and immune function.
Reported in January 2025 as a raise in progress; completion was not confirmed.
The field's most useful negative cases expose assay artifacts, regulatory arbitrage, biomarker substitution, and ordinary clinical failure.
Resveratrol's apparent SIRT1 activation was traced to the assay reagent. GSK had acquired Sirtris for $720M in 2008, then terminated SRT501 in 2010. Source ↗
Commercial plasma transfusions ran ahead of evidence until the FDA issued a 2019 safety warning. Alkahest/Grifols plasma-fraction trials did not deliver a translation.
The AAV-hTERT trial was announced in Colombia outside FDA jurisdiction. Bioethicists flagged the setup; no peer-reviewed results have been published. MIT Technology Review ↗
UBX1325 missed its phase 2b primary endpoint and Nasdaq suspended the listing. Liquidation is reported but lacks a primary corporate or SEC dissolution statement, so it remains probable rather than confirmed. Trial outcome ↗
The Phase 3 NOPARK trial (JAMA, 2026) tested one year of nicotinamide riboside in 410 people with early Parkinson disease. NAD metabolism rose as intended, but there was no clinical benefit and disease scores were slightly worse than placebo — the largest rigorous test of an NAD+ precursor, and a direct demonstration that raising NAD levels is not, by itself, evidence of a clinical effect. Source ↗
There is no prior issue to compare against. This October issue records the archive's opening position so later scans can report genuine changes rather than repeat the landscape.
Near term: functional healthspan evidence, led by mTOR, senolytics, and MSC programs. Long term: partial reprogramming has the strongest mouse effect sizes but lacks human safety data.
Responder stratification for rapamycin and senolytics; p16-targeted reprogramming delivery; persistent MSC effects and TIE-2; cryoprotectant toxicity in organ banking; and standardized biological-age measurement.
No prior monthly issue exists. The October baseline ranks ten directions, records four human-signal trials, separates biological revival from informational preservation, and names five evidence rules.
Promote a direction only if the new evidence improves replication, advances from animal to human, reports a prespecified clinical endpoint, or resolves a named safety or delivery constraint.
Four developments landed after the baseline scan. ER-100, Life Biosciences' OSK partial-reprogramming therapy, reported first-in-human data on 8 October 2026: well tolerated through Day 56 in the first three participants of its glaucoma Phase 1, with dose escalation cleared — company-reported safety data in three people, not evidence that reprogramming works in humans. Porcine kidneys of about 100 g were vitrified with a new cryoprotectant, stored at −150 °C for up to a year, nanowarmed, and recovered function approaching standard cold storage; the work is a bioRxiv preprint reported on 15 October 2026 and has not yet passed peer review. The Phase 3 NOPARK trial of nicotinamide riboside in early Parkinson disease was negative despite raising NAD metabolism. A Nature paper (DOI 10.1038/s41586-026-11152-9) described a BH2/BH4 cold-longevity mechanism — mechanism-stage only, in worms and human cells. The D+Q MASH trial has moved to peer review (Koning et al., Nature Metabolism). Sources for this update were fetched and verified in live sessions on 21 October 2026.
The next credible turn will not be one dramatic headline. It will be independent replication, validated measurement, targeted delivery, and function that lasts.
Selected primary or closest-available sources for the core findings in this brief. The underlying survey used web-search index results gathered on 11 October 2026. On 21 October 2026 every source was fetched and verified in live sessions; three citations did not survive that check and were corrected: a dead link replaced with the primary paper, a link to a removed site replaced with the institution's own page, and one updated to the publisher's new domain.